Koch, Andrea <br/><br/>
Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.  [electronic resource] 

 -  International journal of chronic obstructive pulmonary disease  2014 
 - 697-714 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1178-2005 
<br/><br/><label>Standard No.: </label>10.2147/COPD.S62502  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Adrenergic beta-2 Receptor Agonists--administration & dosage<br/>Aged<br/>Area Under Curve<br/>Benzoxazines--administration & dosage<br/>Bronchodilator Agents--administration & dosage<br/>Drug Administration Schedule<br/>Equipment Design<br/>Ethanolamines--administration & dosage<br/>Female<br/>Forced Expiratory Volume<br/>Formoterol Fumarate<br/>Humans<br/>Lung--drug effects<br/>Male<br/>Middle Aged<br/>Nebulizers and Vaporizers<br/>Predictive Value of Tests<br/>Pulmonary Disease, Chronic Obstructive--diagnosis<br/>Recovery of Function<br/>Respiratory Function Tests<br/>Severity of Illness Index<br/>Surveys and Questionnaires<br/>Time Factors<br/>Treatment Outcome